Adaptive Biotechnologies
Seattle-based Adaptive Biotechnologies provides life science equipment for disease diagnosis and monitoring in the US.
Founded
2009Seattle-based Adaptive Biotechnologies provides life science equipment for disease diagnosis and monitoring in the US.
Adaptive Biotechnologies Corporation, founded in Seattle, Washington, is a commercial-stage company focused on revolutionizing disease diagnosis and treatment through its immune medicine platform. The company's core mission is to harness the adaptive immune system's power to detect and fight diseases, often before symptoms appear. Its primary products include immunoSEQ, a platform for answering translational research questions and discovering new diagnostic signals, and clonoSEQ, a clinical diagnostic tool for monitoring minimal residual disease in multiple myeloma patients.
Notable affiliated individuals include co-founders Chad Robins and Harlan Robins. The company has attracted significant investment from firms like Viking Global Investors and Matrix Capital Management. Key achievements include FDA approval for clonoSEQ and partnerships with major pharmaceutical companies to advance immune-driven therapies. Adaptive Biotechnologies has made a substantial impact by enabling more precise disease monitoring and fostering advancements in personalized medicine.
Companies similar to Adaptive Biotechnologies include Seagen, HI-Bio, Mission Bio and Fluidigm.
Adaptive Biotechnologies was founded in 2009.
Adaptive Biotechnologies' headquarters is located in Seattle, WA, US.
Adaptive Biotechnologies' most recent funding round was for $125M (USD) in September 2022.
As of Sep 12, 2022, Adaptive Biotechnologies has raised a total of $531.9M (USD).
Adaptive Biotechnologies has 790 employees as of Feb 6, 2024.
Mission Bio
